Inactive Instrument

Neos Therapeutics, Inc. Stock price

Equities

NEOS

US64052L1061

Pharmaceuticals

Dynamic Chart
Aytu Biopharma, Inc. Enters into Loan and Security Agreement, by and Among Neos Therapeutics, Inc., Neos Therapeutics Brands, Llc, Neos Therapeutics, Lp, Neos Therapeutics Commercial, Llc, Pharmafab Texas, Llc, Aytu Therapeutics, Llc, Innovus Pharmaceuticals, Inc., Semprae Laboratories, Inc., Novalere, Inc., Supplement Hunt, Inc., and Delta Prime Savings Club, Inc. as Borrowers CI
Aytu BioScience : Completes Merger With Neos Therapeutics MT
Neos Therapeutics, Inc. Announces Board Changes CI
Neos Therapeutics, Inc. Announces Cessation of Richard Eisenstadt as Chief Financial Officer CI
Neos Therapeutics, Inc. Announces Cessation of Gerald Mclaughlin as Chief Executive Officer CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from S&P TMI Index CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from NASDAQ Composite Index CI
Aytu BioScience, Inc. completed the acquisition of Neos Therapeutics, Inc.. CI
Transcript : Neos Therapeutics, Inc. - Shareholder/Analyst Call
Neos Therapeutics : Merger With Aytu BioScience Endorsed by Proxy Advisers Glass, Lewis MT
Aytu BioScience : Neos Therapeutics Shareholders To Vote on Deal In March MT
Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc. CI
DJ Industrial : Wall Street Slips Pre-Bell as Stimulus Impasse Drags, Jobless Claims Surge MT
Neos Therapeutics : Aytu BioScience and Neos Therapeutics Enter Definitive Merger Deal MT
Transcript : Aytu BioScience, Inc., Neos Therapeutics, Inc. - M&A Call
More news
Managers TitleAgeSince
Chief Executive Officer 56 18-06-26
Director of Finance/CFO 55 -
Chief Operating Officer - 04-12-31
Members of the board TitleAgeSince
Chief Executive Officer 56 18-06-26
Director/Board Member 51 09-06-14
More insiders
Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and manufacturing central nervous system (CNS) focused products. The Company markets Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate) and Adzenys-ER (amphetamine), all for the treatment of attention deficit hyperactivity disorder (ADHD). The Company manufactures and markets a generic Tussionex (hydrocodone and chlorpheniramine) (generic Tussionex), for the treatment of cough and upper respiratory symptoms of a cold. It is also developing N-desethyloxybutynin (NT0502), for the treatment of sialorrhea in patients with neurological conditions. NT0502 is a selective anticholinergic agent that is developing an oral, treatment to reduce chronic sialorrhea in patients with neurological conditions associated with salivation and drooling.
More about the company
  1. Stock
  2. Equities
  3. Stock Neos Therapeutics, Inc. - Nasdaq